과제정보
This study was funded by the Korean Gastric Cancer Association, Republic of Korea (grant No. KGC0118C1) and the National Health Insurance Service, Ilsan Hospital (grant No. NHIMC2021CR069). We thank the members of the Surgical Oncology Forum (SOF) study group for their collaboration with this study.
참고문헌
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-249. https://doi.org/10.3322/caac.21660
- Jung KW, Won YJ, Hong S, Kong HJ, Im JS, Seo HG. Prediction of cancer incidence and mortality in Korea, 2021. Cancer Res Treat 2021;53:316-322. https://doi.org/10.4143/crt.2021.290
- Katai H, Ishikawa T, Akazawa K, Isobe Y, Miyashiro I, Oda I, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007). Gastric Cancer 2018;21:144-154. https://doi.org/10.1007/s10120-017-0716-7
- Information Committee of the Korean Gastric Cancer Association. Korean Gastric Cancer Association-led nationwide survey on surgically treated gastric cancers in 2019. J Gastric Cancer 2021;21:221-235. https://doi.org/10.5230/jgc.2021.21.e27
- Nunobe S, Oda I, Ishikawa T, Akazawa K, Katai H, Isobe Y, et al. Surgical outcomes of elderly patients with stage I gastric cancer from the nationwide registry of the Japanese Gastric Cancer Association. Gastric Cancer 2020;23:328-338. https://doi.org/10.1007/s10120-019-01000-3
- Joharatnam-Hogan N, Shiu KK, Khan K. Challenges in the treatment of gastric cancer in the older patient. Cancer Treat Rev 2020;85:101980. https://doi.org/10.1016/j.ctrv.2020.101980
- Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-4393. https://doi.org/10.1200/JCO.2011.36.5908
- Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820. https://doi.org/10.1056/NEJMoa072252
- Chang SH, Kim SN, Choi HJ, Park M, Kim RB, Go SI, et al. Adjuvant chemotherapy for advanced gastric cancer in elderly and non-elderly patients: meta-analysis of randomized controlled trials. Cancer Res Treat 2017;49:263-273. https://doi.org/10.4143/crt.2016.054
- Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1389-1396. https://doi.org/10.1016/S1470-2045(14)70473-5
- Liang Y, Zhao L, Chen H, Lin T, Chen T, Zhao M, et al. Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study. BMC Cancer 2021;21:196. https://doi.org/10.1186/s12885-021-07919-0
- Kunisaki C, Sato S, Tsuchiya N, Kubo H, Watanabe J, Sato T, et al. Real-world therapeutic outcomes of S-1 adjuvant chemotherapy for pStage II/III gastric cancer in the elderly. Eur Surg Res 2021;62:40-52. https://doi.org/10.1159/000515175
- Jin Y, Qiu MZ, Wang DS, Zhang DS, Ren C, Bai L, et al. Adjuvant chemotherapy for elderly patients with gastric cancer after D2 gastrectomy. PLoS One 2013;8:e53149. https://doi.org/10.1371/journal.pone.0053149
- Lee HY, Hwang IG, Park SE, Kim MJ, Park SH, Kang JH, et al. Factors influencing clinicians' choice of adjuvant S-1 versus capecitabine plus oxaliplatin after curative gastrectomy in patients with gastric cancer. J Cancer 2016;7:1711-1715. https://doi.org/10.7150/jca.15598
- Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al. AJCC Cancer Staging Manual. 8th ed. New York: Springer, 2017.
- Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321. https://doi.org/10.1016/S0140-6736(11)61873-4
- Lee CM, Yoo MW, Son YG, Oh SJ, Kim JH, Kim HI, et al. Long-term efficacy of S-1 monotherapy or capecitabine plus oxaliplatin as adjuvant chemotherapy for patients with stage II or III gastric cancer after curative gastrectomy: a propensity score-matched multicenter cohort study. J Gastric Cancer 2020;20:152-164. https://doi.org/10.5230/jgc.2020.20.e13
- Sakuramoto S, Kikuchi S, Watanabe M. Efficacy of S-1 (oral fluoropyrimidine) for gastric cancer. Med Frontline 2009;64:1075-1080.
- Jeong JH, Ryu MH, Ryoo BY, Lee SS, Park I, Lee SH, et al. Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer. Cancer Chemother Pharmacol 2012;70:523-529. https://doi.org/10.1007/s00280-012-1935-6
- Kim HS, Kim JH, Kim JW, Kim BC. Chemotherapy in elderly patients with gastric cancer. J Cancer 2016;7:88-94. https://doi.org/10.7150/jca.13248
- Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-209. https://doi.org/10.1038/nature13480
- Kim JW, Cho SY, Chae J, Kim JW, Kim TY, Lee KW, et al. Adjuvant chemotherapy in microsatellite instability-high gastric cancer. Cancer Res Treat 2020;52:1178-1187.